Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

Nature

Volumn 468, Issue 7320, 2010, Pages 93-97

  Bodin, Karl ^a   Ellmerich, Stephan ^a   Kahan, Melvyn C ^a   Tennent, Glenys A ^a   Loesch, Andrzej ^a   Gilbertson, Janet A ^a   Hutchinson, Winston L ^a   Mangione, Palma P ^a,b   Gallimore, J Ruth ^a   Millar, David J ^a   Minogue, Shane ^a   Dhillon, Amar P ^a   Taylor, Graham W ^a   Bradwell, Arthur R ^c,d   Petrie, Aviva ^e   Gillmore, Julian D ^a   Bellotti, Vittorio ^a,b   Botto, Marina ^f   Hawkins, Philip N ^a   Pepys, Mark B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d Binding Site Group Ltd   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN ANTIBODY; SERUM AMYLOID P; SERUM AMYLOID P ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY; CAUSE OF DEATH; DEVELOPING WORLD; ENZYME ACTIVITY; HEMOPHAGY; RODENT; SERUM;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; GIANT CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMYLOID; AMYLOIDOSIS; ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SERUM AMYLOID P-COMPONENT;

MUS;

EID: 78149282151     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09494     Document Type: Article

References (26)

1. Pepys, M. B. Amyloidosis. Annu. Rev. Med. 57, 223-241 (2006).
2. Pepys, M. B., Dyck, R. F., de Beer, F. C., Skinner, M. & Cohen, A. S. Binding of serum amyloid P component (SAP) by amyloid fibrils. Clin. Exp. Immunol. 38, 284-293 (1979).
3. Pepys, M. B. et al. AmyloidPcomponent. Acriticalreview. Amyloid4, 274-295(1997).
4. Pepys, M. B. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259 (2002).
5. Tennent, G. A., Lovat, L. B. & Pepys, M. B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. Proc. Natl Acad. Sci. USA 92, 4299-4303 (1995).
6. Botto, M. et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Med. 3, 855-859 (1997).
7. Gillmore, J. D. et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br. J. Haematol. 148, 760-767 (2010).
8. Dyck, R. F. et al. Amyloid P-component is a constituent of normal human glomerular basement membrane. J. Exp. Med. 152, 1162-1174 (1980).
9. Breathnach, S. M. et al. AmyloidP componentislocatedonelastic fibre microfibrils of normal human tissues. Nature 293, 652-654 (1981).
10. 123I-labeled serum amyloid P component. J. Exp. Med. 167, 903-913 (1988).
11. Hawkins, P. N. & Pepys, M. B. A primed state exists in vivo following histological regression of amyloidosis. Clin. Exp. Immunol. 81, 325-328 (1990).
12. Botto, M. et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genet. 19, 56-59 (1998).
13. Wessels, M. R. et al. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate anessential role for complement inbothinnate and acquiredimmunity. Proc. NatlAcad. Sci. USA92, 11490-11494 (1995).
14. Van Rooijen, N. & Hendrikx, E. Liposomes for specific depletion of macrophages from organs and tissues. Methods Molec. Biol. 605, 189-203 (2009).
15. Zucker-Franklin, D. Immunophagocytos is of human amyloid fibrils by leukocytes. J. Ultrastruct. Res. 32, 247-257 (1970).
16. Argilés, À., Garća Garć a, M. & Mourad, G. Phagocytosisof dialysis-related amyloid deposits by macrophages. Nephrol. Dial. Transplant. 17, 1136-1138 (2002).
17. Nakamura, Y. et al. A case of hereditary amyloidosis transthyretin variant Met 30 with amyloid cardiomyopathy, less polyneuropathy, and the presence of giant cells. Pathol. Int. 49, 898-902 (1999).
18. Verine, J. et al. Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum. Pathol. 38, 1798-1809 (2007).
19. Weiss, S. W. & Page, D. L. Amyloid nephropathy of Ostertag with special reference to renal glomerular giant cells. Am. J. Pathol. 72, 447-455 (1973).
20. Lachmann, H. J. et al. Outcome in systemic AL amyloidosis in relation to changesin concentration of circulating free immunoglobulin light chains following chemotherapy. Br. J. Haematol. 122, 78-84 (2003).
21. Lachmann, H. J. et al. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356, 2361-2371 (2007).
22. Klaus, G. G. B., Pepys, M. B., Kitajima, K. & Askonas, B. A. Activation of mouse complement by different classes of mouse antibody. Immunology 38, 687-695 (1979).
23. Wall, J. S. et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. doi:10. 1182/blood-2010-03-273797 (3 June 2010).
24. Solomon, A., Weiss, D. T. & Wall, J. S. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother. Radiopharm. 18, 853-860 (2003).
25. Solomon, A., Weiss, D. T. & Wall, J. S. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin. Cancer Res. 9, 3831S-3838S (2003).
26. De Beer, F. C. & Pepys, M. B. Isolation of human C-reactive protein and serum amyloid P component. J. Immunol. Methods 50, 17-31 (1982).